Cybin has announced positive Phase 2 topline safety and efficacy data for its proprietary deuterated psilocybin analogue – CYB003 – for the treatment of major depressive...
Compass Pathways has confirmed that the UK component of its Phase 3 trial investigating psilocybin for treatment-resistant depression has now launched.
Diamond Therapeutics has announced that the first patient has been enrolled in its FDA-authorised UAB-Diamond trial evaluating low-dose psilocybin in patients with demoralization.
Health Canada has given Filament Health authorisation to carry out a Phase 2 clinical trial investigating PEX010 – the company’s botanical psilocybin drug candidate – for...
Researchers from the University of Southern Denmark have established a psilocybin microdosing regimen in rats to help advance microdosing research.
Cybin Inc.
Results from the world’s largest study investigating the ‘naturalistic’ use of psilocybin outside of research settings have shown lasting therapeutic benefits.
A new study investigating a single dose of psilocybin for the treatment of major depressive disorder (MDD) has shown clinically significant levels of reduction in depressive...
A new study has shown how trained human coders were able to identify observable markers of therapeutic connection during psilocybin administration in psychedelic-assisted therapy.
Cybin Inc.
